About Us
Bringing global innovation to Greek healthcare
For more than 20 years, WinMedica has been charting a distinctive path of consistency, growth, and success, making long-term investments in innovation, expertise, and international outreach, with the aim of developing and delivering safe New Therapies.
At a glance
A modern manufacturing company with a global footprint
As a modern manufacturing company whose products treat millions of patients across dozens of countries, Win Medica maintains relationships of trust with the medical community - built on the high quality of its products, the sense of safety it provides, and the responsible manner in which it operates.
Today, Win Medica
-
Produces high value-added generic medicines with advanced pharmaceutical formulations
-
Imports and distributes innovative products from leading research-based pharmaceutical companies
-
Invests significant resources in the development of innovative therapies
Commitment to Health.
Respect for Life.
Our mission
To produce high-quality medicines, adding value to life through health. With consistency, integrity, and respect for the patient who places their trust in us.
Our vision
Commitment to Health. Respect for Life.
What We Stand For
Our values
- Quality
We strictly adhere to high-quality standards in every product and service we provide.
- Innovation
We do not simply aim for better products, but for a better everyday life for people overall. We continuously invest in new knowledge and technology, offering modern therapeutic solutions. This is why AI is an integral part of the chain that connects our idea to our product and ultimately to the end user.
- Sustainability
We view our role as an integral part of human life, contributing positively to the health and well-being of the societies in which we operate.
- Respect
We cultivate ongoing, responsible, and two-way communication with customers, partners, employees, and society as a whole - guided by integrity, transparency, and respect for all.
Our History
From 2008 to today
-
2008 WinMedica founded in Athens
WinMedica is established with a clear focus on delivering high-quality, reliable pharmaceutical solutions to the Greek market.
-
2008-2018 Building strong foundations
A decade of consistent growth, expanding commercial presence across hospitals and primary care while building trust with healthcare stakeholders.
-
2018 Entering a new growth era
WinMedica transitions into a phase of accelerated expansion, driven by portfolio development and strategic investment.
-
2018-2023 Rapid growth & portfolio expansion
Revenue doubles while the company expands into high-value therapeutic areas, strengthening its position in specialty and chronic care.
-
2023 Scaling impact in patient care
WinMedica therapies reach approximately 650,000 patients, reflecting a growing footprint in real-world clinical practice across Greece.
-
2024-2025 Expanding into new therapeutic areas
Entry into weight management, urology, and immunology, reinforcing a diversified and future-ready portfolio.
-
2025 A new transformation phase
Launch of the high-potent manufacturing facility in Tripoli and acceleration of R&D and digital capabilities.
-
2026+ Becoming a vertically integrated pharma company
Advancing towards full integration across commercial, R&D, and manufacturing, with growing international reach.
Our Locations
Our facilities
Headquarters
Marousi -
Headquarters
WinMedica’s Headquarters in Marousi constitute a modern business environment designed to support the company’s dynamic growth and innovation-driven philosophy. With a strong emphasis on functionality, technological excellence, and digital readiness, the facilities leverage contemporary infrastructure and tools that enhance collaboration, decision-making, and team efficiency.
Manufacturing Plant
Tripoli -
Manufacturing Plant
WinMedica’s manufacturing plant in Tripoli, Arcadia, covers a total area of 10,000 sq.m. and has a production capacity of up to 500 million tablets and capsules per year.
The plant commenced operations in 2026 and represents a high-technology manufacturing facility producing solid oral dosage forms (tablets and capsules), primarily serving the fields of oncology, immunology, and central nervous system disorders.
More than 200 people are employed at the facility, fifty of whom work exclusively in the Research and Development Department.
The plant incorporates energy-saving installations, while extensive use of robotics and artificial intelligence is implemented, mainly to automate processes and enhance the production efficiency of its units.